Tag Archives: cluster headache

Eli Lilly’s Approved Migraine Drug Wins FDA OK for Cluster Headache

An Eli Lilly migraine drug that was approved last fall now has the regulatory nod to treat a rarer form of headache that tends to occur in clusters. The FDA on Tuesday approved the Lilly (NYSE: LLY) drug galcanezumab (Emgality) for episodic cluster headaches, which patients experience as one to four headaches per day, each […]

Posted in Indiana, Indiana blog main, Indiana top stories, National blog main, New York blog main, Seattle blog main | Tagged , , , , , , , , , , , , , | Comments Off on Eli Lilly’s Approved Migraine Drug Wins FDA OK for Cluster Headache

Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More

The road to every new drug approval is littered with the remains of earlier failures. Biopharmaceutical companies don’t like to talk about the failures. But it’s earnings season now, so some of them don’t have much choice. Biogen’s (NASDAQ: BIIB) earnings call this week was the first since its Alzheimer’s drug aducanumab failed in a Phase […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More

Teva’s Approved Migraine Drug Fails Again to Blunt Rarer Headache

With a second big clinical failure, Teva Pharmaceutical is abandoning efforts to extend the use of its approved migraine drug to the treatment of cluster headaches, a rarer form of headache that typically affects one side of the head around the eye or the temple. Teva (NYSE: TEVA) said Tuesday that an interim analysis of […]

Posted in Indiana blog main, National blog main, New York, New York blog main, New York top stories, Seattle blog main | Tagged , , , , , , , , , , , , , , | Comments Off on Teva’s Approved Migraine Drug Fails Again to Blunt Rarer Headache

Teva’s Migraine Drug Fails in Phase 3 for Chronic Cluster Headaches

Teva Pharmaceutical’s bid to add a new therapeutic application for its experimental migraine-prevention drug has faltered in a late-stage study. Israel-based Teva (NYSE: TEVA) said Friday that it is stopping a Phase 3 clinical trial testing its drug, fremanezumab, for prevention of chronic cluster headaches. According to the company, an analysis found that the study […]

Posted in Indiana blog main, National, National blog main, San Francisco blog main, Seattle blog main | Tagged , , , , , , , , , , , , , | Comments Off on Teva’s Migraine Drug Fails in Phase 3 for Chronic Cluster Headaches